ArticlePloS one2025
Clinical features and pulmonary infections of diffuse alveolar hemorrhage in rheumatic disease patients.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiffuse alveolar hemorrhage (DAH) is an uncommon but potentially life-threatening pulmonary complication in patients with rheumatic diseases (RD). Immunosuppression, endothelial injury, and systemic inflammation may increase the risk of pulmonary infections, further complicating clinical management and worsening outcomes.
objectiveTo describe the prevalence and factors associated with pulmonary infections in patients with DAH and RD.
methodsWe conducted a retrospective, cross-sectional study including patients diagnosed with DAH and underlying RD at a tertiary care center in Mexico between 2003 and 2023. A logistic regression model was used to identify factors associated with infection.
resultsSeventy-three patients with DAH were included; 31.5% had concurrent pulmonary infection. Systemic lupus erythematosus (68.5%) and ANCA-associated vasculitis (29%) were the most common underlying diseases. Evidence of hemorrhage in bronchoalveolar lavage was significantly more frequent in the infection group (76% vs. 48%; p = 0.02). Bacterial infection was the most common, occurring in 62% of cases, followed by fungal infection at 21%. The 30-day mortality rate was 10%, and infection was not an independent predictor of death. A multivariable logistic regression analysis revealed that male sex (OR 9.8; 95% CI: 2.7-35.3; p < 0.01) and IMV requirement (OR 8.8; 95% CI: 1.7-46.9; p = 0.01) were significantly associated with pulmonary infection.
conclusionPulmonary infections are common in patients with DAH and RD. A relatively low short-term mortality rate was observed in this cohort. Male sex and IMV requirement were associated with infections. Early microbiological assessment and targeted therapy are crucial to optimizing outcomes in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.